|
|
|
|
NICE warns industry on cost-effectiveness
NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help the NHS when it comes to money.Updated draft guidance for Bristol Myers-Squibbs Sprycel (dasatinib) and Novartis Tasigna (nilotinib) for chronic myeloid...
|
|
|
XOMA Plunges on $21M Offering; Is Diabetes Drug Partner Near?
Shares of XOMA Ltd.fell 34.5 percent on Tuesday after the company announced a $21 million registered direct offering of stock and warrants. XOMA sold 42 million units for 50 cents apiece, with each unit consisting of one common share and one five-year...
|
|
|
Cimzia UK Access Scheme Reinforces Marketing Message
_ Cimzia UK Access Scheme Reinforces Marketing Message.
|
|
|
Belgium's UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
Keywords: UCB, Sanofi-Aventis, Teva, USA market, Cimzia, Vimpat, Neupro, Xyzal, ProAir Related Articles 24 September 2009 11 September 2009 10 September 2009 10 August 2009 Recent Articles 1 February 2010 1 February 2010 1 February 2010 Related Discussion...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader
with decision to exit the primary care market in the U.S.Decision maximises U.S. focus and resources on core products UCB announced today that it plans to accelerate its U.S. transition to a purely specialty-focused biopharmaceutical company and will...
|
|
|
UCB (BE) - UCB Accelerates Transition to Become Patient-Centric Global Biopharmaceutical Leader With Decision
Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S. transition to a purely specialty-focused...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the
- 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S.transition to a purely specialty-focused biopharmaceutical company and will exit the primary care market in the U.S., effective 1 March 2010. This...
|
|
|
UCB accelerates transition to become patient-centric global
accelerates transition to become patient-centric global biopharmaceutical leader Bookmark this site Latest UCB accelerates transition to become patient-centric global biopharmaceutical leader Monday 1st February 2010 UCB accelerates transition to become patient...
|
|
|
UCB Accelerates Transition To Become Patient-centric Global Biopharmaceutical Leader With Decision To Exit The
UCB announced that it plans to accelerate its U.S.transition to a purely specialty-focused biopharmaceutical company and will exit the primary care market in the U.S., effective 1 March 2010. This strategic decision impacts the reported 2009 net profit...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the
Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - , Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S. transition to a purely specialty-focused...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.
Author : UCB Category : Press Release News Alerts by Email ( click here ) News | Home BRUSSELS, BELGIUM -- 01/29/10 -- Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the
- 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S.transition to a purely specialty-focused biopharmaceutical company and will exit the primary care market in the U.S., effective 1 March 2010. This...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.
BRUSSELS, BELGIUM -- (MARKET WIRE) -- 01/29/10 -- Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S.
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.
BRUSSELS, BELGIUM -- (MARKET WIRE) -- 01/29/10 -- Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S.
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.
BRUSSELS, BELGIUM -- (MARKET WIRE) -- 01/29/10 -- Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S.
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care mark
BRUSSELS, BELGIUM -- (Marketwire) -- 01/29/10 -- Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S.
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market ..
Decision maximises U.S.focus and resources on core products Brussels, Belgium, 29 January 2010 - 18.15 CET - Press Release, Regulated information - UCB announced today that it plans to accelerate its U.S. transition to a purely specialty-focused...
|
|
|
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.
information - UCB announced today that it plans to accelerate its U.S.transition to a purely specialty-focused biopharmaceutical company and will exit the primary care market in the U.S., effective 1 March 2010. This strategic decision impacts the reported...
|
|
|
Clavis Pharma appoints Olav Helleb
Norwegian cancer drug development company Clavis Pharma has appointed Olav Helleb as its new chief executive.He joins the company on 1 February from UCB Pharma, where he was senior vice president and president of immunology operations. In this position he...
|
|
|
Patient access scheme secures NICE approval for Cimzia
UCB Pharmas Cimzia has been recommended by NICE to treat rheumatoid arthritis but only if a patient access scheme is implemented.Cimzia (certolizumab pegol) can be used on the NHS for adults with severe active rheumatoid arthritis (RA), and UCB...
|
|
|
NICE recommends approval of new rheumatoid arthritis (RA)
Cimzia, the first PEGylated anti-TNF, receives recommendation for approval from NICE for the treatment of severe, active RA in adults Under the Patient Access Scheme the new drug will be available free of charge to every eligible NHS RA patient in England...
|
|
|
NICE Reverses Decision, Recommends Arthritis Drug Cimzia
UCB Pharmas rheumatoid arthritis (RA) treatment Cimzia has won a positive recommendation from the UKs National Institute for Health and Clinical Excellence (N NICE Reverses Decision, Recommends Arthritis Drug Cimzia.
|
|
|
New drug offers hope to rheumatoid arthritis sufferers
NICE is giving more hope for adults living with severe active rheumatoid arthritis as a new drug, Cimzia (certolizumab pegol) is approved for use as a treatment option.This new NHS treatment option, together with its Patient Access Scheme is available...
|
|
|
NHS patients to get new rheumatoid arthritis drug Cimzia - 21 Jan 10
_ NHS patients to get new rheumatoid arthritis drug Cimzia - 21 Jan 10.
|
|
|
NICE recommends approval of new rheumatoid arthritis (RA) treatment cimzia
Cimzia, the first PEGylated anti-TNF, receives recommendation for approval from NICE for the treatment of severe, active RA in adults Under the Patient Access Scheme the new drug will be available free of charge to every eligible NHS RA patient in England...
|
